Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/26202
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | BIELEN, Rob | - |
dc.contributor.author | ROBAEYS, Geert | - |
dc.contributor.author | Schelfhout, Sigrid | - |
dc.contributor.author | Monbaliu, Diethard | - |
dc.contributor.author | Van der Merwe, Schalk | - |
dc.contributor.author | Pirenne, Jacques | - |
dc.contributor.author | Nevens, Frederik | - |
dc.date.accessioned | 2018-06-28T07:25:56Z | - |
dc.date.available | 2018-06-28T07:25:56Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | TRANSPLANT INTERNATIONAL, 31 (5), p. 503-509 | - |
dc.identifier.issn | 0934-0874 | - |
dc.identifier.uri | http://hdl.handle.net/1942/26202 | - |
dc.description.abstract | Currently, nucleos(t)ide analogs (NAs) in monotherapy are favored as prophylaxis against hepatitis B recurrence after liver transplantation. However, in patients at risk of renal failure, renal safety of NAs is of concern. We investigated the safety and efficacy of subcutaneous (SC) hepatitis B immunoglobulins (HBIG) in monotherapy. This is a single-arm prospective trial in patients transplanted >1 year. We included 43 Caucasian patients. The majority was treated with calcineurin inhibitors, and several patients had other risk factors for renal impairment as well: diabetes mellitus (n = 10/43), arterial hypertension (n = 11/43), and hyperlipidemia (=10/43). At inclusion, 42% (n = 18) had chronic kidney disease grade 3a. All patients were switched from IV HBIG with or without NAs to SC HBIG without NAs. After one year, the targeted titer was lowered to 150 IU/l in patients with low risk of recurrence. Mean follow-up time was 36 +/- 5 months. None of the patients had a relapse of HBsAg or HBV DNA. The treatment was well tolerated, safe and the renal function remained unchanged both in patients with (n = 18) or without (n = 25) renal impairment at baseline. The mean HBsAb titer could be decreased from 343 +/- 163 to 199 +/- 81 IU/l in the low-risk group (n = 17) and 218 +/- 71 IU/l in the high-risk group (n = 26). In 86% (n = 37) doses, reductions were possible, which significantly lowered the cost of treatment. SC HBIG without NAs had a 100% success rate in the long-term prevention of HBsAg and HBV DNA reappearance, without deterioration of renal function. | - |
dc.description.sponsorship | This study is part of the Limburg Clinical Research Program (LCRP) UHasselt-ZOL-Jessa, supported by the foundation Limburg Sterk Merk, province of Limburg, Flemish government, Hasselt University, Ziekenhuis Oost-Limburg and Jessa Hospital. Schalk van der Merwe is a Flemish senior researcher mandate (FWO klinische mandaat). All authors approved the final version of the article, including the authorship list. | - |
dc.language.iso | en | - |
dc.subject.other | hepatitis B; immunoglobulin; liver transplantation; nephrotoxicity | - |
dc.title | Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos(t)ide analogs for patients at risk of renal failure after liver transplantation: a prospective single center cohort study | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 509 | - |
dc.identifier.issue | 5 | - |
dc.identifier.spage | 503 | - |
dc.identifier.volume | 31 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Bielen, R (reprint author), Ziekenhuis Oost Limburg, Dept Gastroenterol & Hepatol, Schiepse Bos 6, B-3600 Genk, Belgium. rob.bielen@uhasselt.be | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.1111/tri.13112 | - |
dc.identifier.isi | 000430188200006 | - |
item.accessRights | Open Access | - |
item.fullcitation | BIELEN, Rob; ROBAEYS, Geert; Schelfhout, Sigrid; Monbaliu, Diethard; Van der Merwe, Schalk; Pirenne, Jacques & Nevens, Frederik (2018) Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos(t)ide analogs for patients at risk of renal failure after liver transplantation: a prospective single center cohort study. In: TRANSPLANT INTERNATIONAL, 31 (5), p. 503-509. | - |
item.contributor | BIELEN, Rob | - |
item.contributor | ROBAEYS, Geert | - |
item.contributor | Schelfhout, Sigrid | - |
item.contributor | Monbaliu, Diethard | - |
item.contributor | Van der Merwe, Schalk | - |
item.contributor | Pirenne, Jacques | - |
item.contributor | Nevens, Frederik | - |
item.fulltext | With Fulltext | - |
item.validation | ecoom 2019 | - |
crisitem.journal.issn | 0934-0874 | - |
crisitem.journal.eissn | 1432-2277 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
bielen 1.pdf Restricted Access | Published version | 212.55 kB | Adobe PDF | View/Open Request a copy |
peer reviewed author version.pdf | Peer-reviewed author version | 296.42 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
3
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
3
checked on Apr 24, 2024
Page view(s)
74
checked on Jun 22, 2022
Download(s)
116
checked on Jun 22, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.